Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.28 USD
-0.01 (-0.39%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Spero Therapeutics, Inc. [SPRO/]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Advances; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Advances on Multiple Fronts; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Confirmatory PIVOT-PO Phase 3 Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Pipeline Milestones Imminent; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTM-PD Development FDA Draft Guidance Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued; 2Q23 Financials; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Pivotal Trial Special Protocol Assessment Obtained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Still Attractive With Key Catalysts Gradually Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Poised to Progress; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cash Runway Appears Relatively Lengthy; Pipeline Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
GlaxoSmithKline Rescues Tebipenem; Adjusting PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem HBr Clinical Development Pathway Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Advances; Still Undervalued; 2Q22 Financials; Reducing PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: POLLARD N
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Complete Response Letter Issuance as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Setback Overblown; 1Q22 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Tebipenem Approval Delay; 2021 Financials; Modulating PT to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SPR994 Approval Decision Near-Term; Pipeline Progress; Raising PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R